Literature DB >> 20576297

Bimodal effect of interferon-β on astrocyte proliferation and survival: Importance of nuclear factor-κB.

Olga Barca1, Pablo Devesa-Peleteiro, Marcos Seoane, Rosa M A Señarís, Víctor M Arce.   

Abstract

Accumulating evidence indicates that interferon-β (IFN-β) can modify the complex immunopathogenic scenario causing clinical relapse activity and disease progression in MS. However, the beneficial effects of IFN-β in MS patients may also depend on non-immune mechanisms, including the modulation of astrocyte function. In the present report, we have shown that, depending on the dose, IFN-β treatment can either promote astrocyte proliferation and survival, or result astrocyte death. These actions depend, at least in part, on the regulation of nuclear factor-kappa B (NF-κB), an inducible transcription factor present in neurons and glia. This bimodal effect of IFN-β adds a new layer of complexity in the actions of IFN-β within the CNS.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20576297     DOI: 10.1016/j.jneuroim.2010.05.036

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  4 in total

1.  Negative regulation of human astrocytes by interferon (IFN) α in relation to growth inhibition and impaired glucose utilization.

Authors:  Ting Wang; Yasuhiro Takikawa; Kei Sawara; Yuichi Yoshida; Kazuyuki Suzuki
Journal:  Neurochem Res       Date:  2012-05-25       Impact factor: 3.996

Review 2.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

3.  Relevance of interleukin-10RB to chronic hepatitis B virus infection and biological activities of interferon-λ and interleukin-22.

Authors:  Okki Cho; Jae Youn Cheong; Ka Jung Jun; Soon Sun Kim; Yong-Joon Chwae; Kyongmin Kim; Sun Park; Sung Won Cho
Journal:  Hepatol Int       Date:  2012-03-14       Impact factor: 6.047

Review 4.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.